James M Daly Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for James M Daly.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James M Daly. James M Daly is EVP, Chief Commercial Officer in INCYTE CORP ($INCY) and Exec. VP & Chief Comm. Officer in INCYTE CORP ($INCY) and in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and Director in MADRIGAL PHARMACEUTICALS, INC. ($SNTA) and Director in CHIMERIX INC ($CMRX) and Director in BELLICUM PHARMACEUTICALS, INC ($BLCM).
Latest Insider Trading Transactions of James M Daly
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, BLCM, CMRX, GYHT, INCY, SNTA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 06 2021 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 5,230 | 0 | 26,232 | 21 K to 26.2 K (+24.90 %) |
| Aug 13 2020 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Sell | S | 29.12 | 34,337 | 999,893 | 31,365 | 65.7 K to 31.4 K (-52.26 %) |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | A | 0.00 | 3,059 | 0 | 3,059 | |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | A | 52.73 | 5,579 | 294,181 | 5,579 | |
| Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | Daly James M | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
| Jun 16 2020 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 8.42 | 6,500 | 54,730 | 6,500 | |
| Jun 16 2020 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 8.42 | 6,500 | 54,730 | 6,500 | |
| May 13 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | M | 27.25 | 15,000 | 408,750 | 0 | |
| May 13 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | M | 25.24 | 11,250 | 283,950 | 11,250 | |
| May 13 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Sell | S | 51.13 | 26,250 | 1,342,178 | 0 | 26.3 K to 0 (-100.00 %) |
| May 13 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Buy | M | 27.25 | 15,000 | 408,750 | 26,250 | 11.3 K to 26.3 K (+133.33 %) |
| May 13 2020 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Buy | M | 25.24 | 11,250 | 283,950 | 11,250 | 0 to 11.3 K |
| May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 8,829 | 0 | 65,702 | 56.9 K to 65.7 K (+15.52 %) |
| Sep 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | M | 17.52 | 30,000 | 525,600 | 0 | |
| Sep 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Sell | S | 38.39 | 400 | 15,356 | 0 | 400 to 0 (-100.00 %) |
| Sep 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Sell | S | 37.79 | 29,600 | 1,118,504 | 400 | 30 K to 400 (-98.67 %) |
| Sep 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Buy | M | 17.52 | 30,000 | 525,600 | 30,000 | 0 to 30 K |
| Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | Daly James M | Director | Option Exercise | A | 100.45 | 20,000 | 2,009,000 | 20,000 | |
| Jun 28 2019 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Director | Option Exercise | A | 25.24 | 22,500 | 567,900 | 22,500 | |
| Jun 24 2019 | CMRX | CHIMERIX INC | Daly James M | Director | Option Exercise | A | 3.37 | 21,000 | 70,770 | 21,000 | |
| Jun 14 2019 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 1.96 | 25,000 | 49,000 | 25,000 | |
| May 03 2019 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 12,173 | 0 | 56,873 | 44.7 K to 56.9 K (+27.23 %) |
| Jun 21 2018 | CMRX | CHIMERIX INC | Daly James M | Director | Option Exercise | A | 4.82 | 21,000 | 101,220 | 21,000 | |
| Jun 18 2018 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 9.80 | 10,000 | 98,000 | 10,000 | |
| Jun 08 2018 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 17.52 | 15,000 | 262,800 | 15,000 | ||
| Jun 08 2018 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 17.52 | 15,000 | 262,800 | 15,000 | ||
| May 02 2018 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 10,363 | 0 | 44,700 | 34.3 K to 44.7 K (+30.18 %) |
| Jul 19 2017 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 28.85 | 15,000 | 432,750 | 15,000 | ||
| Jun 29 2017 | CMRX | CHIMERIX INC | Daly James M | Director | Option Exercise | A | 5.53 | 21,000 | 116,130 | 21,000 | |
| Jun 15 2017 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 10.34 | 10,000 | 103,400 | 10,000 | |
| Jun 15 2017 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 10.34 | 10,000 | 103,400 | 10,000 | |
| Jun 14 2017 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 27.25 | 15,000 | 408,750 | 15,000 | ||
| May 05 2017 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 14,135 | 0 | 34,337 | 20.2 K to 34.3 K (+69.97 %) |
| Jun 28 2016 | CMRX | CHIMERIX INC | Daly James M | Director | Option Exercise | A | 3.73 | 9,000 | 33,570 | 9,000 | |
| Jun 17 2016 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 12.44 | 10,000 | 124,400 | 10,000 | |
| Jun 10 2016 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 39.60 | 12,500 | 495,000 | 12,500 | ||
| May 19 2016 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 9.40 | 833 | 7,830 | 833 | |
| May 19 2016 | BLCM | BELLICUM PHARMACEU ... | Daly James M | Director | Option Exercise | A | 9.40 | 20,000 | 188,000 | 20,000 | |
| May 06 2016 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 20,202 | 0 | 20,202 | 0 to 20.2 K |
| Jan 11 2016 | ACAD | ACADIA PHARMACEUTI ... | Daly James M | Option Exercise | A | 28.73 | 15,000 | 430,950 | 15,000 | ||
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 64.55 | 981 | 63,324 | 17,662 | |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 601 | 9,989 | 2,407 | |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 7,331 | 121,841 | 30,928 | |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 18.32 | 2,778 | 50,893 | 16,765 | |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 107.84 | 981 | 105,791 | 3,521 | 4.5 K to 3.5 K (-21.79 %) |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 64.55 | 981 | 63,324 | 4,502 | 3.5 K to 4.5 K (+27.86 %) |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 108.28 | 10,710 | 1,159,679 | 3,521 | 14.2 K to 3.5 K (-75.26 %) |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 601 | 9,989 | 14,231 | 13.6 K to 14.2 K (+4.41 %) |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 7,331 | 121,841 | 13,630 | 6.3 K to 13.6 K (+116.38 %) |
| Jun 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 18.32 | 2,778 | 50,893 | 6,299 | 3.5 K to 6.3 K (+78.90 %) |
| Jun 24 2015 | CMRX | CHIMERIX INC | Daly James M | Director | Option Exercise | A | 45.15 | 9,000 | 406,350 | 9,000 | |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 64.55 | 981 | 63,324 | 18,643 | |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 602 | 10,005 | 3,008 | |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 7,732 | 128,506 | 38,659 | |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 18.32 | 2,778 | 50,893 | 19,543 | |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 106.00 | 981 | 103,986 | 3,521 | 4.5 K to 3.5 K (-21.79 %) |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 64.55 | 981 | 63,324 | 4,502 | 3.5 K to 4.5 K (+27.86 %) |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 106.43 | 11,112 | 1,182,650 | 3,521 | 14.6 K to 3.5 K (-75.94 %) |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 602 | 10,005 | 14,633 | 14 K to 14.6 K (+4.29 %) |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 7,732 | 128,506 | 14,031 | 6.3 K to 14 K (+122.75 %) |
| May 28 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 18.32 | 2,778 | 50,893 | 6,299 | 3.5 K to 6.3 K (+78.90 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 64.55 | 14,718 | 950,047 | 19,624 | |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 18.32 | 5,556 | 101,786 | 22,321 | |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 15,464 | 257,012 | 46,391 | |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 1,203 | 19,994 | 3,610 | |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 107.67 | 14,718 | 1,584,687 | 3,521 | 18.2 K to 3.5 K (-80.70 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 64.55 | 14,718 | 950,047 | 18,239 | 3.5 K to 18.2 K (+418.01 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 107.67 | 22,223 | 2,392,750 | 3,521 | 25.7 K to 3.5 K (-86.32 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 18.32 | 5,556 | 101,786 | 25,744 | 20.2 K to 25.7 K (+27.52 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 15,464 | 257,012 | 20,188 | 4.7 K to 20.2 K (+327.35 %) |
| Apr 24 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 1,203 | 19,994 | 4,724 | 3.5 K to 4.7 K (+34.17 %) |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 602 | 10,005 | 4,813 | |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 16.62 | 7,732 | 128,506 | 61,855 | |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Option Exercise | M | 18.32 | 2,778 | 50,893 | 27,877 | |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 81.77 | 8,334 | 681,471 | 3,521 | 11.9 K to 3.5 K (-70.30 %) |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 602 | 10,005 | 11,855 | 11.3 K to 11.9 K (+5.35 %) |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 16.62 | 7,732 | 128,506 | 11,253 | 3.5 K to 11.3 K (+219.60 %) |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Sell | S | 83.44 | 2,778 | 231,796 | 3,521 | 6.3 K to 3.5 K (-44.10 %) |
| Feb 25 2015 | INCY | INCYTE CORP | Daly James M | EVP, Chief Commerci ... | Buy | M | 18.32 | 2,778 | 50,893 | 6,299 | 3.5 K to 6.3 K (+78.90 %) |
| Oct 23 2012 | INCY | INCYTE CORP | Daly James M | Exec. VP & Chief Co ... | Option Exercise | A | 16.62 | 281,952 | 4,686,042 | 281,952 | |
| Oct 23 2012 | INCY | INCYTE CORP | Daly James M | Exec. VP & Chief Co ... | Option Exercise | A | 16.62 | 18,048 | 299,958 | 18,048 |
Page: 1